Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...

Appointment aligns Board leadership with Company’s transition to clinical-stage development and advancement of KAD-101 for platinum-resistant ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development ...

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

Older patients with hypertension are often inadequately treated due to misconceptions regarding reasonable goal blood pressures or concerns about treatment side effects. Adequately treating ...

PHILADELPHIA — Patients with celiac disease who take an angiotensin receptor blocker (ARB) may experience worse outcomes, such as increased risk of iron deficiency, diarrhea, and abdominal pain, ...

Opioid agonist/antagonist has a big impact in phase IIb trial ...

Please provide your email address to receive an email when new articles are posted on . The addition of leukotriene receptor antagonists to antihistamines improved urticaria symptoms. The combination ...